|1.||Park, Byung Rim: 3 articles (09/2015 - 03/2012)|
|2.||Kim, Min Sun: 3 articles (09/2015 - 03/2012)|
|3.||Jin, Yuan-Zhe: 3 articles (09/2015 - 03/2012)|
|4.||You, Hao-Jun: 3 articles (09/2005 - 09/2002)|
|5.||Arendt-Nielsen, Lars: 3 articles (09/2005 - 09/2002)|
|6.||Li, Li-Wei: 2 articles (05/2015 - 03/2012)|
|7.||Jin, Guang-Shi: 2 articles (05/2015 - 03/2012)|
|8.||Sherry, David M: 2 articles (05/2008 - 01/2007)|
|9.||Frishman, Laura J: 2 articles (05/2008 - 01/2007)|
|10.||Liu, Tong: 2 articles (05/2008 - 12/2007)|
02/01/2010 - "Treatment with RP67580 or AP7 plus CNQX did not attenuate hyperaemia or histological changes, but reduced joint allodynia and swelling. "
07/01/2004 - "In contrast, 36 nmol of CNQX given at either time point reversed allodynia. "
09/30/2002 - "Peripheral administration of AP5, but not CNQX, reduced mechanical allodynia and hyperalgesia. "
11/21/1994 - "Arthritic animals became hyperalgesic to radiant heat stimuli by 4 h and this hyperalgesia was reversed by both CNQX and AP7. "
10/01/1994 - "Therefore, the present results indicate that established joint swelling and hyperalgesia can be reduced significantly by CNQX."
|2.||Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
12/01/1995 - "We demonstrate that neuroprotective effect of CNQX on axotomized motor neurons, raises a possibility that such a agent may have therapeutic potential in motor neuronopathy and amyotrophic lateral sclerosis."
08/29/1994 - "The changes in [3H]kainate binding were observed only in the amyotrophic lateral sclerosis (ALS) subgroup of MND, while the changes in [3H]CNQX binding in the spinal cord were more marked in ALS compared to progressive muscular atrophy (PMA) cases. "
03/01/2000 - "The free radical scavenger alpha-phenyl-N-tert-butylnitrone, the AMPA/kainate receptor blocker 6-cyano-7-nitroquinoxaline-2,3-dione, and riluzole, a drug that is currently used for the treatment of amyotrophic lateral sclerosis, were protective against malonate-induced motoneuron death. "
|3.||AIDS-Related Complex (ARC)
03/15/1997 - "4. In ARC cultures, postsynaptic potentials, both excitatory and inhibitory, were virtually eliminated by the glutamate receptor antagonists AP5 and CNQX, underlining the functional importance of glutamate within this part of the neuroendocrine brain. "
02/01/2011 - "Compared with the control rats, the firing rate of spontaneous discharges in ARC neurons of inflamed rats was significantly higher, and it was significantly reduced both by an NMDA receptor antagonist (MK-801, 300 μmol/L) and by a non-NMDA receptor antagonist (CNQX, 30 μmol/L). "
04/01/2001 - "AMPA receptor antagonists (CNQX) blocked targeting of Arc mRNA in a small region, and mGluR antagonists (MCPG) did not affect localization. "
03/15/1997 - "3. Using microdrop stimulation of presynaptic neurons in ARC slices, we found that local axons from these glutamatergic neurons make local synaptic contact with other neurons in the ARC and that all evoked excitatory postsynaptic potentials could be blocked by the selective ionotropic glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 microM) and D,L-2-amino-5-phosphonovalerate (AP5; 100 microM). "
12/01/1997 - "The efficacy of fentanyl to elicit muscular rigidity in this manner was significantly reduced by previous intrathecal administration of either 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), D-(-)-2-amino-5-phosphonovaleric acid (AP5), or (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP). "
06/26/1992 - "Consistent with these observations, neither APV nor AP3 significantly altered the effect of hypoxia on forebrain cholinergic neurons, while the addition of APV and CNQX in combination protected the phenotype of these neurons only if there was 50% or less loss of phenotype following hypoxia.(ABSTRACT TRUNCATED AT 250 WORDS)"
08/03/1999 - "Exposure of CNQX-treated female rats to hypercapnia, but not to hypoxia transiently decreased TI. "
10/01/1998 - "The alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (18.7 +/- 5.1%, p < 0.001) and mild hypothermia (33.5-34 degrees C) during hypoxia (19.5 +/- 2.7%, p < 0.05) were moderately protective. "
06/12/2003 - "However, pretreatment with kynurenic acid or DL-2-amino-5-phosphonopentanoic acid, but not 6-cyano-7-nitroquinoxaline-2,3-dione, 5 min before hypoxia could effectively prevent the post-hypoxic depression of Glu-induced responses. "
03/01/2002 - "However, in contrast to high K(+)(o)-induced hyperexcitability, hypoxia-induced hyperexcitability was also blocked by the AMPA/kainite-receptor antagonist, CNQX (5 microM). "
|1.||6-Cyano-7-nitroquinoxaline-2,3-dione (6 Cyano 7 nitroquinoxaline 2,3 dione)
|3.||Glutamic Acid (Glutamate)
|4.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|5.||Excitatory Amino Acid Antagonists
|6.||Kainic Acid Receptors (Kainate Receptor)
|7.||3- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid (CPP)
|10.||gamma-glutamylaminomethylsulfonic acid (GAMS)